Shop

Author at Microdose

Ritika Dubey

Ritika Dubey is a reporter covering mental health, drug policies, developments in psychedelics— legal, science, business, and justice— in Canada and the U.S. She began her career as a multimedia journalist with an Indian political magazine Outlook India and moved to Canada in 2019.

Law & Politics

1 Jun 2022

British Columbia Decriminalizes Drug Possession

Psychedelic advocates wanted more, but this decrim measure is a big step in the right direction...

By Ritika Dubey

Industry

19 May 2022

A Deeper Look at Affordability, Insurance, and Access

One of the biggest concerns in the psychedelic industry is affordability....

By Ritika Dubey

Industry, Science

10 May 2022

Psychedelics and the State of Mental Health

The final path is yet to be determined, but it seems increasingly clear that psychedelic medicine will play a significant role in the future of mental health....

By Ritika Dubey

Law & Politics

3 May 2022

Activists Protest the DEA for Psilocybin Access

The law says palliative care patients have the Right To Try psilocybin, yet the DEA is still blocking access...

By Ritika Dubey

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

22 Mar 2022

Access to Psychedelics: Oregon Pushes for Spiritual Psilocybin Use

With places like Oregon being the testing grounds for future models of psychedelic therapy, these kinds of conversations around access and affordability help lay crucial frameworks for others to follow....

By Ritika Dubey

Culture

25 Feb 2022

Ethics in Psychedelics: Fireside Project’s Equity Initiative

The psychedelic industry is growing bigger and stronger by the day across North America, and to make sure it doesn’t leave anyone out, activists have taken an early front seat...

By Ritika Dubey

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.